<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>0379-3982</journal-id>
<journal-title><![CDATA[Revista Tecnología en Marcha]]></journal-title>
<abbrev-journal-title><![CDATA[Tecnología en Marcha]]></abbrev-journal-title>
<issn>0379-3982</issn>
<publisher>
<publisher-name><![CDATA[Instituto Tecnológico de Costa Rica]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S0379-39822023000200109</article-id>
<article-id pub-id-type="doi">10.18845/tm.v36i2.6002</article-id>
<title-group>
<article-title xml:lang="es"><![CDATA[Biomarcadores en el diagnóstico temprano y tratamiento de cáncer]]></article-title>
<article-title xml:lang=""><![CDATA[Biomarkers in the early diagnosis and treatment of cancer]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Camacho-Sánchez]]></surname>
<given-names><![CDATA[Melissa]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Leandro-Vargas]]></surname>
<given-names><![CDATA[Luis Alfredo]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Mendoza-Salas]]></surname>
<given-names><![CDATA[Montserrat]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Meza-Gutiérrez]]></surname>
<given-names><![CDATA[Natalie]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Montero-Zúñiga]]></surname>
<given-names><![CDATA[Fabricio]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
</contrib-group>
<aff id="Af1">
<institution><![CDATA[,Instituto Tecnológico de Costa Rica  ]]></institution>
<addr-line><![CDATA[ ]]></addr-line>
<country>Costa Rica</country>
</aff>
<aff id="Af2">
<institution><![CDATA[,Instituto Tecnológico de Costa Rica  ]]></institution>
<addr-line><![CDATA[ ]]></addr-line>
<country>Costa Rica</country>
</aff>
<aff id="Af3">
<institution><![CDATA[,Instituto Tecnológico de Costa Rica.  ]]></institution>
<addr-line><![CDATA[ ]]></addr-line>
<country>Costa Rica</country>
</aff>
<aff id="Af4">
<institution><![CDATA[,Instituto Tecnológico de Costa Rica  ]]></institution>
<addr-line><![CDATA[ ]]></addr-line>
<country>Costa Rica</country>
</aff>
<aff id="Af5">
<institution><![CDATA[,Instituto Tecnológico de Costa Rica.  ]]></institution>
<addr-line><![CDATA[ ]]></addr-line>
<country>Costa Rica</country>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>06</month>
<year>2023</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>06</month>
<year>2023</year>
</pub-date>
<volume>36</volume>
<numero>2</numero>
<fpage>109</fpage>
<lpage>117</lpage>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://www.scielo.sa.cr/scielo.php?script=sci_arttext&amp;pid=S0379-39822023000200109&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.sa.cr/scielo.php?script=sci_abstract&amp;pid=S0379-39822023000200109&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.sa.cr/scielo.php?script=sci_pdf&amp;pid=S0379-39822023000200109&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="es"><p><![CDATA[Resumen En el presente escrito se destaca la importancia que tienen los biomarcadores en el área biomédica para el desarrollo de tecnologías que permiten el diagnóstico temprano y tratamiento de enfermedades como el cáncer. Se recalcan tres de los biomarcadores para el cáncer que han demostrado ser efectivos para su tratamiento: el antígeno prostático específico (PSA), el cuál es de suma importancia al determinar recurrencias de cáncer de próstata y evaluar la respuesta al tratamiento, el micro ARN (miARN), el cual se muestra alterado en células cancerígenas, y la hormona &#946;-HCG. Este último se puede emplear como marcador tumoral para varios tipos de cáncer y se ha determinado que esta hormona puede actuar como inhibidora de la apoptosis y estimula el crecimiento de células cancerígenas. Además, existe una relación directa entre la concentración de &#946;-HCG y la agresividad del cáncer.]]></p></abstract>
<abstract abstract-type="short" xml:lang="en"><p><![CDATA[Abstract In this paper points up the importance of biomarkers in the biomedical area for the development of technologies that allow early diagnosis and treatment of diseases such as cancer. Three of the biomarkers for cancer that have been shown to be effective for its treatment are highlighted: the prostate specific antigen (PSA), which is of utmost importance when determining recurrences of prostate cancer and evaluating the response to treatment, micro RNA (miRNA), which is altered in cancer cells, and the hormone &#946;-HCG. The latter can be used as a tumor marker for various types of cancer and it has been determined that this hormone can act as an inhibitor of apoptosis and stimulate the growth of cellular cancers. Furthermore, there is a direct relationship between the concentration of &#946;-HCG and the aggressiveness of the cancer.]]></p></abstract>
<kwd-group>
<kwd lng="es"><![CDATA[Antígeno prostático específico]]></kwd>
<kwd lng="es"><![CDATA[miARN]]></kwd>
<kwd lng="es"><![CDATA[hormona &#946;-HCG]]></kwd>
<kwd lng="es"><![CDATA[pruebas preclínicas]]></kwd>
<kwd lng="es"><![CDATA[cáncer de próstata]]></kwd>
<kwd lng="en"><![CDATA[Prostate specific antigen]]></kwd>
<kwd lng="en"><![CDATA[miRNA]]></kwd>
<kwd lng="en"><![CDATA[&#946;-HCG hormone]]></kwd>
<kwd lng="en"><![CDATA[preclinical tests]]></kwd>
<kwd lng="en"><![CDATA[prostate cancer]]></kwd>
</kwd-group>
</article-meta>
</front><back>
<ref-list>
<ref id="B1">
<label>(1)</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Islami]]></surname>
<given-names><![CDATA[F.]]></given-names>
</name>
<name>
<surname><![CDATA[Goding Sauer]]></surname>
<given-names><![CDATA[A.]]></given-names>
</name>
<name>
<surname><![CDATA[Miller]]></surname>
<given-names><![CDATA[K.D.]]></given-names>
</name>
<name>
<surname><![CDATA[Siegel]]></surname>
<given-names><![CDATA[R.L.]]></given-names>
</name>
<name>
<surname><![CDATA[Fedewa]]></surname>
<given-names><![CDATA[S.A.]]></given-names>
</name>
<name>
<surname><![CDATA[Jacobs]]></surname>
<given-names><![CDATA[E.J.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[&#8220;Proportion and number of cancer cases and deaths attributable to potentially modifiable risk factors in the United States&#8221;]]></article-title>
<source><![CDATA[CA: A Cancer Journal for Clinicians. vol. 68, no.1, pp: 31&#8211;54, 2018]]></source>
<year></year>
</nlm-citation>
</ref>
<ref id="B2">
<label>(2)</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Wang]]></surname>
<given-names><![CDATA[X.]]></given-names>
</name>
<name>
<surname><![CDATA[Kaczor-Urbanowicz]]></surname>
<given-names><![CDATA[K.E.]]></given-names>
</name>
<name>
<surname><![CDATA[Wong]]></surname>
<given-names><![CDATA[D.T.W.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[&#8220;Salivary biomarkers in cancer detection&#8221;]]></article-title>
<source><![CDATA[Medical Oncology. Humana Press Inc., vol. 34, 2017.]]></source>
<year>2017</year>
</nlm-citation>
</ref>
<ref id="B3">
<label>(3)</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Siegel]]></surname>
<given-names><![CDATA[R.L.]]></given-names>
</name>
<name>
<surname><![CDATA[Miller]]></surname>
<given-names><![CDATA[K.D.]]></given-names>
</name>
<name>
<surname><![CDATA[Fuchs]]></surname>
<given-names><![CDATA[H.E.]]></given-names>
</name>
<name>
<surname><![CDATA[Jemal]]></surname>
<given-names><![CDATA[A.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[&#8220;Cancer Statistics, 2021&#8221;]]></article-title>
<source><![CDATA[CA: A Cancer Journal for Clinicians. vol. 71, no. 1, pp: 7&#8211;33, 2021.]]></source>
<year>2021</year>
</nlm-citation>
</ref>
<ref id="B4">
<label>(4)</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Mayeux]]></surname>
<given-names><![CDATA[R.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[&#8220;Biomarkers: Potential Uses and Limitations&#8221;]]></article-title>
<source><![CDATA[The Journal of the American Society for Experimental NeuroTherapeutics, vol. 1, no. 2, pp: 182-188, 2004.]]></source>
<year>2004</year>
</nlm-citation>
</ref>
<ref id="B5">
<label>(5)</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Palacios]]></surname>
<given-names><![CDATA[G.]]></given-names>
</name>
<name>
<surname><![CDATA[Pedrero-Chamizo]]></surname>
<given-names><![CDATA[R.]]></given-names>
</name>
<name>
<surname><![CDATA[Palacios]]></surname>
<given-names><![CDATA[N.]]></given-names>
</name>
<name>
<surname><![CDATA[Maroto-Sánchez]]></surname>
<given-names><![CDATA[B.]]></given-names>
</name>
<name>
<surname><![CDATA[Aznar]]></surname>
<given-names><![CDATA[S.]]></given-names>
</name>
<name>
<surname><![CDATA[González-Gross]]></surname>
<given-names><![CDATA[M.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[&#8220;Biomarcadores de la actividad física y del deporte&#8221;]]></article-title>
<source><![CDATA[Rev Esp Nutr Comunitaria. vol. 21, pp: 235&#8211;42, 2015.]]></source>
<year>2015</year>
</nlm-citation>
</ref>
<ref id="B6">
<label>(6)</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Arango]]></surname>
<given-names><![CDATA[V.]]></given-names>
</name>
<name>
<surname><![CDATA[Sandra]]></surname>
<given-names><![CDATA[S.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[&#8220;Biomarcadores para la evaluación de riesgo&#8221;]]></article-title>
<source><![CDATA[Revista Facultad Nacional de Salud Pública, vol. 30, no. 1, pp:75&#8211;82, 2012.]]></source>
<year>2012</year>
</nlm-citation>
</ref>
<ref id="B7">
<label>(7)</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Verma]]></surname>
<given-names><![CDATA[M.]]></given-names>
</name>
<name>
<surname><![CDATA[Rosenfeld]]></surname>
<given-names><![CDATA[S.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[&#8220;Challenges for Biomarkers in Cancer Detection&#8221;]]></article-title>
<source><![CDATA[Annals of The New York Academy of Sciences. vol. 1022, pp: 9&#8211;16, 2004.]]></source>
<year>2004</year>
</nlm-citation>
</ref>
<ref id="B8">
<label>(8)</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Sethi]]></surname>
<given-names><![CDATA[S.]]></given-names>
</name>
<name>
<surname><![CDATA[Ali]]></surname>
<given-names><![CDATA[S.]]></given-names>
</name>
<name>
<surname><![CDATA[Philip]]></surname>
<given-names><![CDATA[P.A.]]></given-names>
</name>
<name>
<surname><![CDATA[Sarkar]]></surname>
<given-names><![CDATA[F.H.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[&#8220;Clinical advances in molecular biomarkers for cancer diagnosis and therapy&#8221;.]]></article-title>
<source><![CDATA[International Journal of Molecular Sciences, vol. 14, pp. 71&#8211;84, 2013.]]></source>
<year>2013</year>
</nlm-citation>
</ref>
<ref id="B9">
<label>(9)</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Aronson and R. E. Ferner]]></surname>
<given-names><![CDATA[J. K.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[&#8220;Biomarkers&#8212;A General Review,&#8221;]]></article-title>
<source><![CDATA[Current Protocols in Pharmacology, vol. 76, no. 1, 2017. doi: 10.1002/cpph.19.]]></source>
<year>2017</year>
</nlm-citation>
</ref>
<ref id="B10">
<label>(10)</label><nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[&#8220;Triple negative breast cancer: A thorough review of biomarkers,&#8221;]]></article-title>
<source><![CDATA[Critical Reviews in Oncology/Hematology, vol. 145, p. 102855, 2020. doi: 10.1016/j.critrevonc.2019.102855.]]></source>
<year>2020</year>
</nlm-citation>
</ref>
<ref id="B11">
<label>(11)</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Buder-Bakhaya and J. C. Hassel]]></surname>
<given-names><![CDATA[K.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[&#8220;Biomarkers for Clinical Benefit of Immne Checkpoint Inhibitor Treatment&#8212;A Review From the Melanoma Perspective and Beyond,&#8221;]]></article-title>
<source><![CDATA[Frontiers in Immunology, vol. 9, 2018, doi: 10.3389/fimmu.2018.01474.]]></source>
<year>2018</year>
</nlm-citation>
</ref>
<ref id="B12">
<label>(12)</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Filella y L. Foj]]></surname>
<given-names><![CDATA[X.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[&#8220;Prostate Cancer Detection and Prognosis: From Prostate Specific Antigen (PSA) to Exosomal Biomarkers&#8221;]]></article-title>
<source><![CDATA[Int J Mol Sci, vol. 17, no. 11, pp. 1784, Oct. 2016. doi: http://doi.org/10.3390/ijms17111784]]></source>
<year>2016</year>
</nlm-citation>
</ref>
<ref id="B13">
<label>(13)</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Lilja]]></surname>
<given-names><![CDATA[H.]]></given-names>
</name>
<name>
<surname><![CDATA[Oldbring]]></surname>
<given-names><![CDATA[J.]]></given-names>
</name>
<name>
<surname><![CDATA[Rannevik y C. Laurell]]></surname>
<given-names><![CDATA[G.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[&#8220;Seminal vesicle-secreted proteins and their reactions during gelation and liquefaction of human semen&#8221;.]]></article-title>
<source><![CDATA[J Clin Invest, vol. 80, no. 2, pp. 281-285, 1987. doi: 10.1172 / JCI113070.]]></source>
<year>1987</year>
</nlm-citation>
</ref>
<ref id="B14">
<label>(14)</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Gretzer y A. W. Partin]]></surname>
<given-names><![CDATA[M. B.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[&#8220;PSA markers in prostate cancer detection&#8221;]]></article-title>
<source><![CDATA[Urol Clin North Am, vol. 30, no. 4, pp. 677-686, Nov. 2003. doi: 10.1016 / s0094-0143 (03) 00057-0.]]></source>
<year>2003</year>
</nlm-citation>
</ref>
<ref id="B15">
<label>(15)</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Stenman]]></surname>
<given-names><![CDATA[U. H.]]></given-names>
</name>
<name>
<surname><![CDATA[Leinonen]]></surname>
<given-names><![CDATA[J.]]></given-names>
</name>
<name>
<surname><![CDATA[Alfthan]]></surname>
<given-names><![CDATA[H.]]></given-names>
</name>
<name>
<surname><![CDATA[Rannikko]]></surname>
<given-names><![CDATA[S.]]></given-names>
</name>
<name>
<surname><![CDATA[Tuhkanen y O.A. Alfthan]]></surname>
<given-names><![CDATA[K.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[&#8220;Complex between Prostate-specific Antigen and &#945;1-Antichymotrypsin Is the Major Form of Prostate-specific Antigen in Serum of Patients with Prostatic Cancer: Assay of the Complex Improves Clinical Sensitivity for Cancer&#8221;]]></article-title>
<source><![CDATA[Cancer Res, vo. 51, no. 1, 1991.]]></source>
<year>1991</year>
</nlm-citation>
</ref>
<ref id="B16">
<label>(16)</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Balk]]></surname>
<given-names><![CDATA[S. P.]]></given-names>
</name>
<name>
<surname><![CDATA[Ko y G. J. Bubley]]></surname>
<given-names><![CDATA[Y. J.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[&#8220;Biology of Prostate-Specific Antigen&#8221;.]]></article-title>
<source><![CDATA[J Clin Oncol, vol. 21, no. 2, pp. 383-91, Sep. 2016. doi: 10.1200 / JCO.2003.02.083]]></source>
<year>2003</year>
</nlm-citation>
</ref>
<ref id="B17">
<label>(17)</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Adhyam y A. K. Gupta]]></surname>
<given-names><![CDATA[M.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[&#8220;A Review on the Clinical Utility of PSA in Cancer Prostate&#8221;]]></article-title>
<source><![CDATA[Indian J Surg Oncol, vol. 3, no. 2, pp. 120-129, Jun. 2012. doi: 10.1007 / s13193-012-0142-6.]]></source>
<year>2012</year>
</nlm-citation>
</ref>
<ref id="B18">
<label>(18)</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Hermida Lazcano]]></surname>
<given-names><![CDATA[I.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[&#8220;Marcadores Tumorales&#8221;]]></article-title>
<source><![CDATA[Rev Clin Med Fam, vo. 9, no. 1, pp. 31-42, Feb. 2016.]]></source>
<year>2016</year>
</nlm-citation>
</ref>
<ref id="B19">
<label>(19)</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Gregorio]]></surname>
<given-names><![CDATA[E.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[&#8220;Comparison between PSA density, free PSA percentage and PSA density in the transition zone in the detection of prostate cancer in patients with serum PSA between 4 and 10 ng/m&#8221;]]></article-title>
<source><![CDATA[Int Braz J Urol. , vol. 33, no. 2, pp. 151-160, 2007. doi: 10.1590 / s1677-55382007000200004.]]></source>
<year>2007</year>
</nlm-citation>
</ref>
<ref id="B20">
<label>(20)</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Sturgeon]]></surname>
<given-names><![CDATA[C. M.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[&#8220;National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines for Use of Tumor Markers in Testicular, Prostate, Colorectal, Breast, and Ovarian Cancers&#8221;]]></article-title>
<source><![CDATA[Clin Chem, vol. 54, no. 12, pp. e11-79., Dic. 2008. doi: 10.1373 / clinchem.2008.105601.]]></source>
<year>2008</year>
</nlm-citation>
</ref>
<ref id="B21">
<label>(21)</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Fabbri]]></surname>
<given-names><![CDATA[M.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[&#8220;miRNAs as molecular biomarkers of cancer&#8221;.]]></article-title>
<source><![CDATA[Expert Review of Molecular Diagnostics, vol. 10, no. 4, pp. 435-444, 2010. doi: 10.1586/erm.10.27]]></source>
<year>2010</year>
</nlm-citation>
</ref>
<ref id="B22">
<label>(22)</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Lan]]></surname>
<given-names><![CDATA[H.]]></given-names>
</name>
<name>
<surname><![CDATA[Wang]]></surname>
<given-names><![CDATA[X.]]></given-names>
</name>
<name>
<surname><![CDATA[Jin]]></surname>
<given-names><![CDATA[H.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[&#8220;MicroRNAs as potential biomarkers in cancer: opportunities and challenges&#8221;]]></article-title>
<source><![CDATA[BioMed Research International, vol. 2015, Article ID 125094, 2015. doi: 10.1155/2015/125094]]></source>
<year>2015</year>
</nlm-citation>
</ref>
<ref id="B23">
<label>(23)</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Mishra]]></surname>
<given-names><![CDATA[P.J.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[&#8220;MicroRNAs as promising biomarkers in cancer diagnostics&#8221;]]></article-title>
<source><![CDATA[Biomark Res, vol. 2, no. 19, 2014. doi: 10.1186/2050-7771-2-19]]></source>
<year>2014</year>
</nlm-citation>
</ref>
<ref id="B24">
<label>(24)</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Zhao]]></surname>
<given-names><![CDATA[M.]]></given-names>
</name>
<name>
<surname><![CDATA[Zou]]></surname>
<given-names><![CDATA[X.]]></given-names>
</name>
<name>
<surname><![CDATA[Zhou and Z. Bai]]></surname>
<given-names><![CDATA[J.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[&#8220;MicroRNA polymorphism: A target for diagnosis and prognosis of hepatocellular carcinoma? (Review)&#8221;]]></article-title>
<source><![CDATA[Oncol Lett., vol. 21, no. 4, 2021 doi: 10.3892/ol.2021.12586]]></source>
<year>2021</year>
</nlm-citation>
</ref>
<ref id="B25">
<label>(25)</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Kölbl]]></surname>
<given-names><![CDATA[A.C.]]></given-names>
</name>
<name>
<surname><![CDATA[Schlenk]]></surname>
<given-names><![CDATA[K.]]></given-names>
</name>
<name>
<surname><![CDATA[Behrendt]]></surname>
<given-names><![CDATA[N.]]></given-names>
</name>
<name>
<surname><![CDATA[Andergasse]]></surname>
<given-names><![CDATA[U.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[&#8220;The importance of hcg in human endometrial adenocarcinoma and breast cancer&#8221;.]]></article-title>
<source><![CDATA[International Journal of Biological Markers, vol 33, no. 1, pp. 33-39, 2018.]]></source>
<year>2018</year>
</nlm-citation>
</ref>
<ref id="B26">
<label>(26)</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Haslam]]></surname>
<given-names><![CDATA[C.]]></given-names>
</name>
<name>
<surname><![CDATA[Damiati]]></surname>
<given-names><![CDATA[S.]]></given-names>
</name>
<name>
<surname><![CDATA[Whitley]]></surname>
<given-names><![CDATA[T.]]></given-names>
</name>
<name>
<surname><![CDATA[Davey]]></surname>
<given-names><![CDATA[P.]]></given-names>
</name>
<name>
<surname><![CDATA[Ifeachor]]></surname>
<given-names><![CDATA[E.]]></given-names>
</name>
<name>
<surname><![CDATA[Awan]]></surname>
<given-names><![CDATA[S.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[&#8220;Label-Free Sensors Based on Graphene Field-Effect Transistors for the Detection of Human Chorionic Gonadotropin Cancer Risk Biomarker&#8221;.]]></article-title>
<source><![CDATA[Diagnostics, vol. 8, no. 1, 2018.]]></source>
<year>2018</year>
</nlm-citation>
</ref>
<ref id="B27">
<label>(27)</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Zhou]]></surname>
<given-names><![CDATA[Y.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[&#8220;Human Chorionic Gonadotropin &#946; Induces Migration and Invasion via Activating ERK1/2 and MMP-2 in Human Prostate Cancer DU145 Cells&#8221;.]]></article-title>
<source><![CDATA[PLoS ONE, vol. 8, no. 2, 2013.]]></source>
<year>2013</year>
</nlm-citation>
</ref>
<ref id="B28">
<label>(28)</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Iles]]></surname>
<given-names><![CDATA[R.K.]]></given-names>
</name>
<name>
<surname><![CDATA[Delves]]></surname>
<given-names><![CDATA[P.J.]]></given-names>
</name>
<name>
<surname><![CDATA[Butler]]></surname>
<given-names><![CDATA[S.A.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[&#8220;Does hCG or hCG&#946; play a role in cancer cell biology?&#8221;]]></article-title>
<source><![CDATA[Molecular and Cellular Endocrinology, vol. 329, no. 1-2, pp. 62&#8211;70, 2010.]]></source>
<year>2010</year>
</nlm-citation>
</ref>
<ref id="B29">
<label>(29)</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Sengodan]]></surname>
<given-names><![CDATA[S.K.]]></given-names>
</name>
<name>
<surname><![CDATA[Nadhan]]></surname>
<given-names><![CDATA[R.]]></given-names>
</name>
<name>
<surname><![CDATA[Nair]]></surname>
<given-names><![CDATA[R.S.]]></given-names>
</name>
<name>
<surname><![CDATA[Hemalatha]]></surname>
<given-names><![CDATA[S.K.]]></given-names>
</name>
<name>
<surname><![CDATA[Somasundaram]]></surname>
<given-names><![CDATA[V.]]></given-names>
</name>
<name>
<surname><![CDATA[Sushama]]></surname>
<given-names><![CDATA[R.R.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[&#8220;BRCA1 regulation on &#946;-hCG: A mechanism for tumorigenicity in BRCA1 defective breast cancer&#8221;]]></article-title>
<source><![CDATA[Oncogenesis, vol. 6, no. 9, 2017.]]></source>
<year>2017</year>
</nlm-citation>
</ref>
<ref id="B30">
<label>(30)</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Marchán]]></surname>
<given-names><![CDATA[J.C.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[&#8220;Gonadotropina coriónica humana, una hormona versátil y un marcador tumoral esencial en cáncer testicular de células germinales no seminomatosas&#8221;]]></article-title>
<source><![CDATA[Revista Colombiana de Endocrinología, Diabetes &amp; Metabolismo, vol. 6, no. 2, pp. 107&#8211;113, 2019.]]></source>
<year>2019</year>
</nlm-citation>
</ref>
<ref id="B31">
<label>(31)</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Nwabuobi]]></surname>
<given-names><![CDATA[C.]]></given-names>
</name>
<name>
<surname><![CDATA[Arlier]]></surname>
<given-names><![CDATA[S.]]></given-names>
</name>
<name>
<surname><![CDATA[Schatz]]></surname>
<given-names><![CDATA[F.]]></given-names>
</name>
<name>
<surname><![CDATA[Guzeloglu-Kayisli]]></surname>
<given-names><![CDATA[O.]]></given-names>
</name>
<name>
<surname><![CDATA[Lockwood]]></surname>
<given-names><![CDATA[C.J.]]></given-names>
</name>
<name>
<surname><![CDATA[Kayisli]]></surname>
<given-names><![CDATA[U.A.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[&#8220;hCG: Biological functions and clinical applications&#8221;.]]></article-title>
<source><![CDATA[International Journal of Molecular Sciences, vol.18, no.10, pp. 1&#8211;15, 2017.]]></source>
<year>2017</year>
</nlm-citation>
</ref>
<ref id="B32">
<label>(31)</label><nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[&#8220;Cancer biomarker discovery: Current status and future perspectives&#8221;]]></article-title>
<source><![CDATA[International Journal of Radiation Biology. vol. 90, no.8, pp:659&#8211;77, 2014.]]></source>
<year></year>
</nlm-citation>
</ref>
<ref id="B33">
<label>(33)</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Mordente]]></surname>
<given-names><![CDATA[A.]]></given-names>
</name>
<name>
<surname><![CDATA[Meucci]]></surname>
<given-names><![CDATA[E.]]></given-names>
</name>
<name>
<surname><![CDATA[Martorana]]></surname>
<given-names><![CDATA[G.E.]]></given-names>
</name>
<name>
<surname><![CDATA[Silvestrini]]></surname>
<given-names><![CDATA[A.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[&#8220;Cancer biomarkers discovery and validation: State of the art, problems and future perspectives&#8221;]]></article-title>
<source><![CDATA[Advances in Experimental Medicine and Biology. pp: 9&#8211;26, 2015.]]></source>
<year>2015</year>
</nlm-citation>
</ref>
<ref id="B34">
<label>(34)</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Kretschmer]]></surname>
<given-names><![CDATA[A.]]></given-names>
</name>
<name>
<surname><![CDATA[Tilki]]></surname>
<given-names><![CDATA[D.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[&#8220;Biomarkers in prostate cancer &#8211; Current clinical utility and future perspectives&#8221;]]></article-title>
<source><![CDATA[Critical Reviews in Oncology/Hematology, vol. 120, pp: 180&#8211;93, 2017.]]></source>
<year>2017</year>
</nlm-citation>
</ref>
</ref-list>
</back>
</article>
